logo
logo
BCPC stock ticker logo

Balchem Corporation

NASDAQ•BCPC
CEO: Mr. Theodore L. Harris
Sector: Basic Materials
Industry: Chemicals - Specialty
Listing Date: 1986-06-03
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Contact Information
5 Paragon Drive, Montvale, NJ, 07645, United States
845-326-5600
www.balchem.com
Market Cap
$5.47B
P/E (TTM)
35.3
33.7
Dividend Yield
0.6%
52W High
$183.90
52W Low
$139.17
52W Range
67%
Rank21Top 7.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$263.62M+0.00%
4-Quarter Trend

EPS

$1.22+0.00%
4-Quarter Trend

FCF

$94.55M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Sales Increased 8.8% Net sales totaled $1.04B in 2025, reflecting 8.8% growth driven by all segments compared to 2024 results.
Net Earnings Grew 20.5% Net earnings reached $154.85M, showing strong 20.5% improvement driven by margin expansion and higher sales volume.
Operating Margin Expanded to 20.2% Operating margin improved to 20.2% of net sales, up from 19.2% in 2024, reflecting better cost control across operations.
Human Nutrition Sales Up 9.9% HNH segment sales grew 9.9% to $659.39M, contributing significantly to overall company revenue growth for the fiscal year.

Risk Factors

Raw Material Shortages Risk Reliance on global sourcing subjects sales and operations to supply chain disruptions and inflationary cost pressures impacting margins.
Ethylene Oxide Regulatory Headwinds EPA Interim Decision on EtO use limits applications and imposes mitigation measures, potentially increasing customer costs and limiting sales.
Intense Market Competition Risks Competition in animal feed and supplement markets is highly price sensitive, potentially limiting pricing power and margin maintenance.
Evolving Cybersecurity Threat Landscape Continuous, evolving cybersecurity attacks, including AI-driven methods, pose risks to systems, data integrity, and operational continuity.

Outlook

Capital Expenditures Projected 2026 Capital expenditures projected between $40.00M and $45.00M for 2026, supporting growth and efficiency projects across facilities.
Drive Efficiency and Differentiation Strategy focuses on leveraging scientific data for human nutrition differentiation and driving production efficiencies in commodity markets.
Active Pursuit of Acquisitions Expect operations to generate sufficient cash flow to fund working capital, investments, and actively pursue additional acquisition candidates.

Peer Comparison

Revenue (TTM)

SSL stock ticker logoSSL
$27.95B
-12.5%
CE stock ticker logoCE
$9.54B
-7.2%
AXTA stock ticker logoAXTA
$5.12B
-3.0%

Gross Margin (Latest Quarter)

PRM stock ticker logoPRM
59.9%
-4.5pp
EGO stock ticker logoEGO
49.3%
-13.1pp
SSRM stock ticker logoSSRM
46.2%
+13.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ESI$7.55B39.37.3%31.9%
EGO$7.30B14.412.4%19.3%
SSL$7.21B51.81.6%36.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.7%
Moderate Growth
4Q Net Income CAGR
1.9%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:Apr 22, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data